IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare

Access to genomic testing, not therapy cost, is the biggest challenge

GlycoNex wins Japan nod to launch first human trial of lead program in gastrointestinal cancers

The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy

Chiba University study flags allergy risk in high-binding antibody drugs

For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms

Transgene and NEC join forces to advance personalized cancer vaccine

TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor

Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer

The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)

Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan

Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema

Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy

Arcellx develops innovative immunotherapies for cancer and other incurable diseases

Genprex bags major patent wins in Japan & Europe for REQORSA cancer therapy

The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer